Kyn Therapeutics aims to disrupt immunosuppressive metabolic pathways and stimulate an anti-tumor immune response, potentially enhancing the effects of other cancer immunotherapies. Kyn is developing a clinical-stage EP4 antagonist as well as two candidates targeting the highly characterized IDO/TDO/kynurenine pathway.
| Headquarters | Cambridge, MA |
| Website | www.kyntherapeutics.com |
| Pipeline | Clinical |
| @KynTherapeutics​ | |
| Partners | Celgene |